title: Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.
abstract: OBJECTIVE
  The prospective trials evaluating the safety and efficacy of intravenous tissue plasminogen activator have generally been conducted at academic medical centers and community hospitals with an institutional commitment to stroke care. Relatively little is known about the safety of this therapy as it is used in the community. We therefore examined outcomes in acute stroke patients treated with thrombolysis using the largest discharge database available in the United States for the years 1999 to 2002.
  
  
  METHODS
  Data were derived from the Nationwide Inpatient Sample for the years 1999 to 2002. Using the appropriate International Classification of Disease-Clinical Modification, 9th revision, codes, patients admitted through the emergency room with a primary diagnosis of acute ischemic stroke were selected for analysis. From these patients, those coded as receiving thrombolysis were identified. Multivariate logistic regression was performed on the thrombolysis and nonthrombolysis cohorts to identify independent predictors of in-hospital mortality from among those clinical elements available in the database.
  
  
  RESULTS
  We identified 2594 patients treated with thrombolysis from a group of 248,964 patients admitted through the emergency room with a primary diagnosis of acute ischemic stroke. The thrombolysis cohort had a higher in-hospital mortality rate compared with the nonthrombolysis patients (11.4% versus 6.8%). The rate of intracerebral hemorrhage was 4.4% for the thrombolysis cohort and 0.4% for nonthrombolysis patients. Multivariate logistic regression showed advanced age, Asian/Pacific Islander race, congestive heart failure, and atrial fibrillation/flutter to be independent predictors of in-hospital mortality after thrombolysis. Thrombolysis volume, overall ischemic stroke volume, and teaching status were not significant predictors of in-hospital mortality after thrombolysis.
  
  
  CONCLUSIONS
  Thrombolysis, as it is used in the community, has a safety profile that is similar to that observed in the large, prospective clinical trials.
authors.affiliation: Columbia Presbyterian Medical College for Physicians and Surgeons, Columbia University, New York, NY, USA.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Bateman
authors.forename: H Christian
authors.initials: HC
authors.lastname: Schumacher
authors.forename: Bernadette
authors.initials: B
authors.lastname: Boden-Albala
authors.forename: Mitchell F
authors.initials: MF
authors.lastname: Berman
authors.forename: J P
authors.initials: JP
authors.lastname: Mohr
authors.forename: Ralph L
authors.initials: RL
authors.lastname: Sacco
authors.forename: John
authors.initials: J
authors.lastname: Pile-Spellman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006753:Hospital Records; D006801:Humans; D007511:Ischemia / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011446:Prospective Studies; D012044:Regression Analysis; D012307:Risk Factors; D020521:Stroke / Q000401:mortality* / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
chemical_list: D010959:Tissue Plasminogen Activator